Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation

Analysis of the literature and guideline review

Carrie S. Oliphant, Justin McCullough, Taimoor Hashim, Rami Khouzam

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hypertrophic cardiomyopathy (HCM), which was first described in 1958, occurs in approximately one in 500 people. Patients with HCM are at an increased risk of atrial fibrillation, which is not only poorly tolerated in this population, but also increases their risk of an embolic event. The incidence of stroke in HCM patients with atrial fibrillation is approximately 21-23%. Given the high risk of stroke, antithrombotic therapy with warfarin is recommended in national guidelines. This therapy should be used without regard to other risk factors for stroke that may be present. Anticoagulation with the new oral anticoagulants may be considered as an alternative; although, specific data for patients with HCM is not available. The purpose of this review is to remind practitioners of the importance of stroke prophylaxis with oral anticoagulants in this population.

Original languageEnglish (US)
Pages (from-to)229-233
Number of pages5
JournalFuture Cardiology
Volume10
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Vitamin K
Hypertrophic Cardiomyopathy
Atrial Fibrillation
Stroke
Guidelines
Anticoagulants
Warfarin
Population
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation : Analysis of the literature and guideline review. / Oliphant, Carrie S.; McCullough, Justin; Hashim, Taimoor; Khouzam, Rami.

In: Future Cardiology, Vol. 10, No. 2, 01.01.2014, p. 229-233.

Research output: Contribution to journalArticle

@article{22b7294b2cb9455fba78b5babee04ae9,
title = "Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation: Analysis of the literature and guideline review",
abstract = "Hypertrophic cardiomyopathy (HCM), which was first described in 1958, occurs in approximately one in 500 people. Patients with HCM are at an increased risk of atrial fibrillation, which is not only poorly tolerated in this population, but also increases their risk of an embolic event. The incidence of stroke in HCM patients with atrial fibrillation is approximately 21-23{\%}. Given the high risk of stroke, antithrombotic therapy with warfarin is recommended in national guidelines. This therapy should be used without regard to other risk factors for stroke that may be present. Anticoagulation with the new oral anticoagulants may be considered as an alternative; although, specific data for patients with HCM is not available. The purpose of this review is to remind practitioners of the importance of stroke prophylaxis with oral anticoagulants in this population.",
author = "Oliphant, {Carrie S.} and Justin McCullough and Taimoor Hashim and Rami Khouzam",
year = "2014",
month = "1",
day = "1",
doi = "10.2217/fca.13.109",
language = "English (US)",
volume = "10",
pages = "229--233",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation

T2 - Analysis of the literature and guideline review

AU - Oliphant, Carrie S.

AU - McCullough, Justin

AU - Hashim, Taimoor

AU - Khouzam, Rami

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hypertrophic cardiomyopathy (HCM), which was first described in 1958, occurs in approximately one in 500 people. Patients with HCM are at an increased risk of atrial fibrillation, which is not only poorly tolerated in this population, but also increases their risk of an embolic event. The incidence of stroke in HCM patients with atrial fibrillation is approximately 21-23%. Given the high risk of stroke, antithrombotic therapy with warfarin is recommended in national guidelines. This therapy should be used without regard to other risk factors for stroke that may be present. Anticoagulation with the new oral anticoagulants may be considered as an alternative; although, specific data for patients with HCM is not available. The purpose of this review is to remind practitioners of the importance of stroke prophylaxis with oral anticoagulants in this population.

AB - Hypertrophic cardiomyopathy (HCM), which was first described in 1958, occurs in approximately one in 500 people. Patients with HCM are at an increased risk of atrial fibrillation, which is not only poorly tolerated in this population, but also increases their risk of an embolic event. The incidence of stroke in HCM patients with atrial fibrillation is approximately 21-23%. Given the high risk of stroke, antithrombotic therapy with warfarin is recommended in national guidelines. This therapy should be used without regard to other risk factors for stroke that may be present. Anticoagulation with the new oral anticoagulants may be considered as an alternative; although, specific data for patients with HCM is not available. The purpose of this review is to remind practitioners of the importance of stroke prophylaxis with oral anticoagulants in this population.

UR - http://www.scopus.com/inward/record.url?scp=84899499208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899499208&partnerID=8YFLogxK

U2 - 10.2217/fca.13.109

DO - 10.2217/fca.13.109

M3 - Article

VL - 10

SP - 229

EP - 233

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 2

ER -